Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes

R J Lewis1, K J Nielsen, D J Craik

  • 1Centre for Drug Design and Development (3D Centre), Institute for Molecular Bioscience, Department of Physiology and Pharmacology, CSIRO Tropical Agriculture, and Queensland Agricultural Biotechnology Centre (QDPI), Australia. r.lewis@mailbox.uq.edu.au

Insights

Four novel omega-conotoxins were discovered, with CVID showing high selectivity for N-type calcium channels. This discovery may lead to new pain management therapies by targeting specific channel variants.

Area of Science:

  • Marine Biology
  • Neuropharmacology
  • Biochemistry

Background:

  • Omega-conotoxins targeting N-type calcium channels are valuable for severe pain management.
  • The venom of Conus catus is a source of novel conotoxins with therapeutic potential.

Purpose of the Study:

  • To discover and characterize new omega-conotoxins from Conus catus venom.
  • To evaluate the selectivity and potency of novel conotoxins, particularly CVID, for N-type calcium channels.

Main Methods:

  • Assay-guided fractionation and gene cloning were used to isolate new conotoxins.
  • Radioligand binding assays and electrophysiological studies (Xenopus oocytes) assessed channel selectivity and inhibition.
  • 1H NMR spectroscopy was employed to determine the structural features of CVID.

Main Results:

  • Four new omega-conotoxins (CVIA-D) were identified from Conus catus venom.
  • CVID exhibited high selectivity for N-type over P/Q-type calcium channels and inhibited rat vas deferens contractions.
  • CVID and MVIIA potency increased significantly in the absence of beta(3) subunits, especially CVID at the alpha(1B-d) splice variant.

Conclusions:

  • The novel omega-conotoxin CVID possesses unique structural features and high selectivity for N-type calcium channels.
  • The differential effects of beta(3) subunits on CVID and MVIIA potency highlight specific interactions with N-type calcium channel variants.
  • The distinct properties of CVID suggest potential for developing targeted pain therapeutics.